NEW YORK (GenomeWeb News) – Enzo Biochem said today that it has acquired the US assets and stock of the two UK subsidiaries of Biomol International for $18 million in cash and stock, plus earn-outs over the next two years.
Privately held Biomol sells enzymes, peptides, substrates, and antibodies for signal transduction, lipid research, apoptosis, neuroscience and drug discovery, with a research focus on the functional proteomics field. The firm has annual revenues of roughly $11.5 million with 9 percent annual growth, according to New York-based Enzo.
“Coupling Biomol with our acquisition of Axxora Life Sciences less than a year ago, we have succeeded in transforming Enzo Life Sciences into a global manufacturer and marketer of reagents and systems spanning a wide spectrum of scientific applications,” Barry Weiner, president of Enzo, said in a statement.
Biomol has 50 employees in the US and UK. Enzo did not say whether they would all join the firm’s operations. However, it said that Biomol’s senior management and founders would remain “actively involved” with Enzo.